Atai Beckley N.V.
ATAI evidence brief
What we can confirm
- Market Cap:
- $2.73B
What it means
What to watch
Prepared research question
What matters most for ATAI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATAI
Atai Beckley N.V. (ATAI) is a clinical-stage biopharmaceutical company focused on developing psychedelic and non-psychedelic therapies for difficult-to-treat mental health conditions, with a lead program in Phase 3 for treatment-resistant depression.
Key risk: Clinical trial failure
Market Cap
$2.73B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Atai Beckley N.V. (ATAI) is a clinical-stage biopharmaceutical company focused on developing psychedelic and non-psychedelic therapies for difficult-to-treat mental health conditions, with a lead program in Phase 3 for treatment-resistant depression.
- Atai Beckley was formed in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited [sec_mda · as of 2026-05-12].
- Cash and cash equivalents were $168.8M as of June 30, 2026, with total revenue of $1.7M and a net loss of $32.5M for the period [sec].
- The lead pipeline candidate is BPL-003 (mebufotenin benzoate) nasal spray, which is being advanced into a Phase 3 pivotal program for treatment-resistant depression [sec · filed 2025-10-21].
- The company also has ongoing Phase 2 trials for VLS-01 (buccal film DMT) and EMP-01 (oral R-MDMA) [sec · filed 2025-10-21].
- Atai Beckley has incurred significant losses and negative cash flows since inception, with an accumulated deficit not specified in the provided data [sec_mda · as of 2026-08-11].
What works
- The company has a diversified pipeline of psychedelic and non-psychedelic compounds targeting mental health disorders with significant unmet need [sec_mda · as of 2026-08-11].
- Clinical studies have demonstrated the potential safety and efficacy profile of psychedelics, particularly their rapid onset and sustained efficacy after a short course of administration [sec_mda · as of 2026-03-06].
- The company estimates its existing cash, cash equivalents, and short-term investments will fund operations into the second half of 2027, based on current operating plans [sec · filed 2025-07-01].
What to weigh
- The company has incurred significant losses and negative cash flows from operations since its inception [sec_mda · as of 2026-08-11].
- The company's ability to continue as a going concern depends on successful clinical development and future financing, which is uncertain [sec_mda · as of 2026-08-11].
- There can be no assurance that milestone payments related to the CVRs for BPL-003 and VLS-01 programs will be made [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
The company is a clinical-stage biopharmaceutical company formed in 2025.
“AtaiBeckley Inc. ("AtaiBeckley", "Company"), headquartered in New York, New York, was founded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited ("Beckley Psytech").”
SEC MD&A · May 12, 2026
Cash and cash equivalents were $168.8M as of June 30, 2026.
“As of June 30, 2026, the Company had cash and cash equivalents of $ 168.8 million and short-term securities”
SEC MD&A · August 11, 2026
The company plans to fund Phase 3 for BPL-003 through top-line data readout.
“funding the planned Phase 3 clinical program for BPL-003 (mebufotenin benzoate) nasal spray through the top-line data readout from the first Phase 3 clinical trial”
SEC filings · October 21, 2025
The company has incurred significant losses and negative cash flows since inception.
“The Company has incurred significant losses and negative cash flows from operations since its inception.”
SEC MD&A · August 11, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial failure — BPL-003 Phase 3 or other pipeline trials may fail to meet endpoints, leading to loss of investment [sec · filed 2025-10-21].
- Cash runway uncertainty — Cash runway estimate depends on assumptions that may prove incorrect; company could use capital sooner than expected [sec · filed 2025-07-01].
- Regulatory and milestone risk — CVR milestone payments for BPL-003 and VLS-01 are not guaranteed and depend on achieving specified development and regulatory milestones [sec_mda · as of 2026-08-11].
- Going concern risk — Significant losses and negative cash flows raise doubt about ability to continue as a going concern without additional financing [sec_mda · as of 2026-08-11].
What to watch
- Top-line data readout from the first Phase 3 clinical trial of BPL-003 for treatment-resistant depression [sec · filed 2025-10-21].
- Completion of the Phase 2 clinical trial of VLS-01 (buccal film DMT) [sec · filed 2025-10-21].
- Completion of the Phase 2a study for EMP-01 (oral R-MDMA) [sec · filed 2025-10-21].
- Cash burn rate and any future financing events, given the company's significant losses [sec_mda · as of 2026-08-11].
Sources: News · SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run Atai Beckley N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Atai Beckley N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
176
Total value held
$348.5M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 12,000,000 | $42.5M |
| vanguard capital management llc | 11,761,398 | $41.6M |
| ubs group ag | 7,426,867 | $26.3M |
| blackrock, inc. | 6,835,300 | $24.2M |
| adage capital partners gp, l.l.c. | 5,642,758 | $20.0M |
| susquehanna international group, llp | 5,286,326 | $18.7M |
| millennium management llc | 4,364,096 | $15.4M |
| morgan stanley | 3,852,772 | $13.6M |
| candriam s.c.a. | 3,086,379 | $10.9M |
| qube research & technologies ltd | 2,891,942 | $10.2M |
Showing top 10 of 176 institutional holders of Atai Beckley N.V.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 7.3%
- Days to cover
- 3.3
- Shares short
- 22,819,769
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATAI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Atai Beckley N.V.?
Atai Beckley N.V. (ATAI) is a clinical-stage biopharmaceutical company focused on developing psychedelic and non-psychedelic therapies for difficult-to-treat mental health conditions, with a lead program in Phase 3 for treatment-resistant depression.
Who is the CEO of Atai Beckley N.V.?
Dr. Srinivas G. Rao M.D., Ph.D. is the chief executive officer of Atai Beckley N.V. (ATAI).
Where is Atai Beckley N.V. headquartered?
Atai Beckley N.V. (ATAI) is headquartered in New York, NY, United States.
What therapeutic areas does Atai Beckley N.V. focus on?
Atai Beckley N.V. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.